1.50
-0.04(-2.60%)
Currency In USD
| Previous Close | 1.54 |
| Open | 1.49 |
| Day High | 1.54 |
| Day Low | 1.47 |
| 52-Week High | 12.45 |
| 52-Week Low | 1.22 |
| Volume | 24,566 |
| Average Volume | 549,820 |
| Market Cap | 4.84M |
| PE | 21.43 |
| EPS | 0.07 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 2.73 |
| Change | -0.04 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $5.34 as of September 30, 2025 at a share price of $1.5. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 1 year ago, it would be worth $240 as of September 30, 2025 at a share price of $1.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 12:02 PM GMT
WASHINGTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today th
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 21, 2025 12:31 PM GMT
WASHINGTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it
60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
GlobeNewswire Inc.
Aug 19, 2025 12:54 PM GMT
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to a robust patient population wi